Zavesca
About Zavesca:
- Zavesca contains the active substance Miglustat which is a glucosylceramide synthase inhibitor intended as monotherapy for the treatment of adult patients with mild/moderate type 1 Gaucher disease when enzyme replacement therapy is not left as an option.
- Zavesca is used to treat two inherited diseases that affect the way how body handles fats. Both diseases lead to the accumulation of fatty substances called glycosphingolipids in the body.
Strength:
Miglustat 100 mg of capsules, white opaque hard gelatin capsules.
Recommended Dosage:
- The recommended dose is 100 mg capsule administered orally three times a day at regular intervals.
- If a dose is missed, the next capsule should be taken at the next scheduled time.
- The dose should be reduced to one 100 mg capsule once or twice a day in patients due to adverse reactions like tremors or diarrhea.
Warnings & Precautions:
- Peripheral neuropathy: Follow-ups to be done with neurological evaluations at 6-month intervals in such patients.
- Tremor: Dose to be reduced to ameliorate tremor or discontinue treatment if it is not resolved within days of dose reduction.
- Diarrhea and weight loss: Gastrointestinal disease evaluation to be performed in patients who are not showing any response to usual interventions.
- Reductions in Platelet Count: Mild reductions in platelet counts without association with bleeding are observed so monitoring of platelet counts is recommended.
Common Zavesca Side Effects
- Diarrhea
- Weight loss
- Stomach pain
- Gas
- Nausea and vomiting
- Headache including migraine
- Tremor
- Leg cramps
- Dizziness
- Weakness
- Vision problems
- Thrombocytopenia
- Muscle cramps
- Back pain,
- Constipation
- Dry mouth
- Heaviness in arms and legs
- Memory loss
- Unsteady walking
- Anorexia
- Indigestion
- Paresthesia
- Stomach bloating and pain not related to food
- Menstrual changes
Use in Specific Population
Pregnancy: Zavesca may cause fetal harm when administered to a pregnant woman. Zavesca use in pregnancy is insufficient to assess a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There are risks associated with symptomatic Type I Gaucher disease in pregnancy, including hepatosplenomegaly and thrombocytopenia.
Pediatric use: The safety and effectiveness of Zavesca in pediatric patients have not been established yet.
Storage and Handling
- Stored at 20°C to 25°C (68°F to 77°F).
- Excursions are permitted between 15°C to 30°C (59°F to 86°F).
- Keep out of reach of children.
For the medicine procurement, we follow a simple four-step process.
- Enquiry about the medicine: When you request information about the medication you require, we will handle your data. Our Named Access Program Support team will contact you within 24 hours to assist.
- Verification Process: In our mission to help patients access medications that may not be approved or readily accessible in their home countries, Sansfro ensures the verification of medicine availability and approval. Additionally, we thoroughly review the patient’s prescription and medical information for accuracy and compliance.
- Sourcing the Medicine: Upon successfully completing the verification process, our team will initiate contact with our network of suppliers to source the required medication for you. Subsequently, our team works diligently to obtain the most favorable quotes for your medicines and oversees the processing of your order.
- Safe Delivery: We will coordinate the secure delivery of your consignment upon approval of the final quote. Our team of logistics specialists is available to provide consignment tracking assistance. Acknowledging that the Named Access Program industry is susceptible to unauthorized channels is essential. To uphold the safe and legal provision of medications, we rigorously adhere to Standard Operating Procedures.
For the importation of medication, we will require the following documents from the patient:
- An authentic prescription copy.
- A proof of identity document.
- Information about the healthcare provider in charge.
- A current residential address.
Once all these documents are provided, the Sansfro team will begin the import license application process. This license is a crucial requirement to facilitate the procurement of the necessary medication upon receiving government approval.
No news found.
About Sansfro
Sansfro is committed to bridging the healthcare gap. Our purpose is to bring hope and healing to patients suffering from rare diseases by linking them with life-saving treatments through our Named Patient Program. Join us in our quest for a better and healthier world.
Know More...FAQ'S
What are the active ingredients of Zavesca?
Zavesca is available in capsule form and contains the active ingredient Miglustat.
How Zavesca is administered?
Take Zavesca at the same time each day and if you miss a dose, skip that dose. Take the next capsule at the usual time.
What are the possible serious side effects of Zavesca?
The most common side effects are numbness, tingling, pain, or burning in your hands or feet, new or worsening hand tremors, diarrhea, weight loss, and low platelet counts.
Which indication Zavesca is used for?
Zavesca is a prescription medicine used to treat adults with mild to moderate type 1 Gaucher disease. Zavesca is used in patients who cannot be treated with enzyme replacement therapy.
What is cost of Zavesca in India?
For enquiry related to Zavesca price kindly reach out to our Patient Support Team at (+91) 9315705373 or help@sansfro.com
Dr Anchal Aryan
Medical counselor
Patient Stories
Word Wide Delivery:
India, Andorra, Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe, Afghanistan, Albania, Algeria, American Samoa, Angola, Anguilla, Antarctica, etc.
